Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
37.85
79.22
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hangzhou Tigermed Consulting Co Ltd
Other Current Assets
Hangzhou Tigermed Consulting Co Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Other Current Assets
ÂĄ127.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-8%
|
||
WuXi AppTec Co Ltd
SSE:603259
|
Other Current Assets
ÂĄ300.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
||
Pharmaron Beijing Co Ltd
SZSE:300759
|
Other Current Assets
ÂĄ268.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
||
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Other Current Assets
ÂĄ1.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
||
Genscript Biotech Corp
HKEX:1548
|
Other Current Assets
$72.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Other Current Assets
ÂĄ119.8m
|
CAGR 3-Years
89%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Hangzhou Tigermed Consulting Co Ltd
Glance View
Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.
See Also
What is Hangzhou Tigermed Consulting Co Ltd's Other Current Assets?
Other Current Assets
127.9m
CNY
Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Other Current Assets amounts to 127.9m CNY.
What is Hangzhou Tigermed Consulting Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
-8%
Over the last year, the Other Current Assets growth was 23%. The average annual Other Current Assets growth rates for Hangzhou Tigermed Consulting Co Ltd have been 16% over the past three years , 15% over the past five years , and -8% over the past ten years .